Elevated levels of eicosapentaenoic acid (EPA) and alpha-linolenic acid (ALA) in serum phosphatidylcholine (PC) at the time of ST-segment elevation myocardial infarction (STEMI) are associated with a lower risk of clinical adverse events during a long-term follow-up, according to a study, suggesting that consumption of foods rich in EPA and ALA may improve STEMI prognosis.
In patients with critical limb ischaemia (CLI) due to chronic total occlusions in the infrapopliteal region, drug-coated balloon (DCB) angioplasty was associated with a lower rate of late lumen loss compared with the standard balloon angioplasty – percutaneous transluminal angioplasty (PTA), according to the results of the IN.PACT below-the-knee (BTK) feasibility study presented at TCT 2020.
Elderly patients with nonvalvular atrial fibrillation (AF) aged ≥80 years who cannot receive oral anticoagulants at recommended doses may do well instead on low-dose edoxaban, which prevents stroke without increasing the incidence of bleeding, according to the results of the phase III ELDERCARE-AF trial.
Treatment with dual antiplatelet therapy (DAPT) after PCI* can safely be shortened to 1 or 3 months without raising ischaemic risk in select patients with high bleeding risk, according to the XIENCE 90/28 trials presented at TCT 2020.
The recent National Health and Morbidity Survey (NHMS) 2019 revealed diabetes is on the uptrend, with about 18.3 percent of persons above the age of 18 being diagnosed with type 2 diabetes. This amounts to about 3.9 million persons living with diabetes in the country.
Using mobile health (mHealth) devices to screen for atrial fibrillation (AF) comes with steep upfront costs but can reduce the incidence of stroke, according to a recent study. Such technology bears more benefit for high-risk patients, as defined by the CHA2DS2-VASc* score.
Initiation of sacubitril-valsartan combo during hospitalization in Asian patients with heart failure with reduced ejection fraction (HFrEF) appears to lead to a higher incidence of adverse drug reactions (ADRs) and treatment discontinuation when compared with starting the patients on the drug as an outpatient, according to real-world data.